Yubo International Biotech Ltd. engages in the supply of products that process, store, and administer therapeutic doses of endometrial stem cells for the treatment of disease and injuries. The company is headquartered in Beijing, Beijing and currently employs 18 full-time employees. The firm focuses on the research and development and application of endometrial stem cells and offers its products and services under the brand VIVCELL. The Company’s product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. The firm also offers stem cell related services including cell testing and health management consulting services.
最新の財務諸表(Form-10K)によると、Yubo International Biotech Ltdの総資産は$1で、純損失は$-1です。
YBGJの主要な財務比率は何ですか?
Yubo International Biotech Ltdの流動比率は0.33、純利益率は0、1株当たり売上高は$0です。
Yubo International Biotech Ltdの収益はセグメントまたは地域別にどのように分けられていますか?
Yubo International Biotech Ltd の最大収益セグメントは Health Management and Health Maintenance Services で、最新の利益発表における収益は 604,676 です。地域別に見ると、China が Yubo International Biotech Ltd の主要市場であり、収益は 604,676 です。
Yubo International Biotech Ltdは収益を上げていますか?
いいえ、最新の財務諸表によると、Yubo International Biotech Ltdの純損失は$-1です。